Important event

Genscript Bio (01548): Legend Biotech announces positive overall survival results for the key CARTITUDE-4 Phase III trial for the treatment of multiple myeloma.

Henlius (02696): The international multicenter Phase III clinical trial of Hansi Joint Bevacizumab Injection combined with chemotherapy for first-line treatment of metastatic colorectal cancer has been approved for use in Japan.

Bonds

BJ Ent Water Group (00371) plans to issue medium-term notes not exceeding RMB 1 billion.

Guolian Securities (01456) received approval from the China Securities Regulatory Commission for the public issuance of subordinated corporate bonds to professional investors.

Repurchase/Shareholding

Alibaba-SW (09988) has spent USD 5.8 billion to repurchase 613 million common stocks as of the end of June.

Tencent (00700) spent approximately HKD 1 billion to repurchase 2.71 million shares on July 2nd.

Meituan-W (03690) spent HKD 500 million to repurchase 4.4773 million shares on July 2nd.

Pax Global (00327) spent HKD 53.0574 million to repurchase 9.75 million shares on July 2nd.

Xiaomi Group-W (01810) spent HKD 49.7924 million on repurchasing 3 million shares on July 2nd.

Skyworth Group (00751) spent HKD 20.499 million to repurchase 6.7 million shares on July 2nd.

Simcere Pharma (02096) spent HKD 14.8815 million to repurchase 2.74 million shares on July 2nd.

Operating Performance

Xpeng (09868) delivered 10,668 smart electric vehicles in June, up by 24% YoY and 5% compared to the previous month.

MicroPort Neurotech (02172) Announces Positive Profit Alert: Expects Mid-Term Revenue to Increase by Approximately 34%-37% YoY to between RMB 400 million and 410 million.

China Vanke (02202) had contract sales of RMB 25.13 billion in June, down 30.46% YoY.

Country Garden (02007): The contract sales amount attributable to company's shareholders in June was about RMB 4.3 billion.

For more details, please refer to the CITIC Securities website ().